Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
177 studies found for:    Open Studies | "Mycobacterium Infections"
Show Display Options
Rank Status Study
21 Recruiting Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection
Condition: Latent Tuberculosis Infection
Intervention:
22 Recruiting Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis
Conditions: Latent Tuberculosis Infection;   Tuberculosis
Intervention:
23 Recruiting PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis
Condition: Cystic Fibrosis
Intervention:
24 Recruiting PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis
Condition: Cystic Fibrosis
Intervention:
25 Recruiting Collection of Lung Fluid and Tissue Samples for Research
Conditions: Mycobacterium Infections, Atypical;   Granulomatous Disease, Chronic;   Job's Syndrome;   Influenza, Human
Intervention:
26 Recruiting Infant TB Infection Prevention Study
Condition: Tuberculosis
Intervention: Drug: Isoniazid
27 Recruiting Performance of IGRAs for TB Infection Diagnosis in Elderly
Conditions: Ageing;   Tuberculosis
Intervention: Other: Blood samples
28 Recruiting Benin Population Diversity of Tuberculosis and Implications
Condition: Tuberculosis
Intervention: Other: No intervention (observational study)
29 Recruiting Serological Test for the Diagnosis of TB
Condition: Active Tuberculosis
Intervention: Other: No intervention
30 Recruiting DAR-901 TB Booster Vaccine to Prevent TB in Adolescents
Condition: Tuberculosis
Interventions: Biological: DAR-901;   Biological: Sterile saline placebo
31 Recruiting Rituximab for Anti-cytokine Autoantibody-Associated Diseases
Conditions: Anticytokine Autoantibody-Associated Diseases;   Disseminated Non-Tuberculous Mycobacteria;   Chronic Mucocutaneous Candidiasis;   Pulmonary Alveolar Proteinosis (PAP)
Intervention: Drug: Rituximab/Rituxan
32 Recruiting Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana
Conditions: Mansonella Perstans Infection;   Buruli Ulcer;   Tuberculosis;   Co-infection
Intervention: Drug: Doxycycline
33 Recruiting Challenge Model for Assessment of Human TB Immunity
Condition: Tuberculosis
Intervention: Biological: BCG TICE strain
34 Recruiting Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis
Conditions: Hemoptysis;   Haemoptysis;   Lung Disease;   Pneumonia;   Tuberculosis;   Bronchiectasis;   Respiratory Tract Infections;   Respiratory Tract Diseases;   Bronchitis;   Mycobacterium Infections;   Bronchial Disease;   Pulmonary Hemorrhage;   Signs and Symptoms;   Signs and Symptoms, Respiratory;   Pathologic Processes;   Mycosis;   Hemorrhage;   Lung Cancer;   Pulmonary Embolism;   Arteriovenous Fistula
Intervention:
35 Recruiting Effect of Xpert MTB/RIF on Patient Outcomes
Condition: Tuberculosis
Intervention: Device: Xpert
36 Recruiting Training Protocol on the Natural History of Tuberculosis
Condition: Tuberculosis
Intervention:
37 Recruiting Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection
Condition: Tuberculosis
Interventions: Dietary Supplement: Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis;   Other: Placebo
38 Recruiting Study of Nontuberculous Mycobacterial Lung Disease
Condition: Nontuberculous Mycobacterial Lung Disease
Intervention:
39 Recruiting A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis
Conditions: Multidrug Resistant Tuberculosis;   Pediatric
Interventions: Drug: 100 mg Delamanid;   Drug: 50 mg Delamanid;   Drug: 25 mg Pediatric Formulation Delamanid;   Drug: (Dose to be determined) Pediatric Formulation Delamanid;   Drug: Optimized Background Regimen (OBR)
40 Recruiting Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis
Conditions: Multidrug Resistant Tuberculosis;   Pediatric
Interventions: Drug: 100 mg Delamanid;   Drug: 50 mg Delamanid;   Drug: 25 mg Pediatric Formulation Delamanid;   Drug: (Dose to be determined) Pediatric Formulation Delamanid;   Drug: Optimized Background Regimen (OBR)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.